Clinical trial · Observational
ACCEPTABILITY AND WRITING FREQUENCY OF ADVANCED DIRECTIVES IN ONCO-DERMATOLOGY PATIENTS
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The law about advance directives is evolving but, in France, few people write it. Te main endpoint of this research is to estimate the proportion of patients who have written their advance directives or considering doing so in onco-dermatologic population. If this rate remains low, some insights on the reasons will be able to be advanced looking at the point of view and opinion of patients about this topic. Seconds endpoints are : For patients against or not planning to write it, understand their reasons Estimate the proportion of patients requesting information and understand how they would like to receive it. Investigate a possible association between the stage of the oncological disease and the positioning of the patient concerning advance directives.
Conditions
Conditions (7)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advance Directives | — | UNRESOLVED | — |
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
| Metastatic Basal Cell Carcinoma | Basal Cell Carcinoma | CURATED_BROADER | 0.78 |
| Oncology | — | UNRESOLVED | — |
| Skin Cancer | Malignant Skin Neoplasm | ALIAS | 0.90 |
| Skin Lymphoma | Cutaneous Lymphoma | ALIAS | 0.90 |
| Skin Squamous Cell Carcinoma | Skin Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| no intervention, only complete a survey | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- patients accepting to answer to the survey
- description
- patients with a skin lymphoma OR melanoma OR advanced skin squamous cell carcinoma OR advanced basal cell carcinoma accepting to answer to the anonymous survey
- interventionNames
- Other: no intervention, only complete a survey
Primary outcomes (1)
- measure
- Writing by the patient of its advance directives
- timeFrame
- when the patient complete the survey
- description
- Writing by the patient of his advance directves and, if not writing, positioning of the patient (rather favorable or rather unfavorable) as to the writing of his advance directives.
Secondary outcomes (2)
- measure
- reason for not writing advance directives
- timeFrame
- when the patient complete the survey
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: \> 18 ya With one of the diagnoses below: * Melanoma * Skin lymphoma * Meckel Carcinoma * localy advanced or metastatic Basal cell carcinoma or squamous cell carcinoma Exclusion Criteria: Patients not in possession of all of its cognitive abilities Patients who can't read patients who don't speak french
References
Publications (0)
Data not yet available